How is the COLARIS® test performed?

There are now two ways to obtain a sample from the patient for analysis.  A small amount of blood can be drawn, or an oral sample can be taken using a buccal rinse.  A sample is sent to Myriad Genetics for DNA sequencing analysis of MLH1, MSH2, MSH6, PMS2 and MYH. COLARIS can also detect large rearrangements in MLH1, MSH2, MSH6, EPCAM, PMS2 and MYH that will not be identified by gene sequencing.

How long does it take for COLARIS test results?

Results take up to 21 days and are sent to the ordering healthcare provider.

If a patient has already been diagnosed with cancer, what does a positive COLARIS result indicate?

Individuals with Lynch syndrome gene mutations are at greater risk for developing a new cancer, in either the colon, endometrium or other areas.  Knowing a patient’s genetic status can help reduce this risk or detect another potential cancer at an early, more treatable stage.  Importantly, a patient’s test results also have significant meaning for the health of his or her family members.

Are gene-specific and single-site tests still available on the TRF?

Yes.  These tests can be ordered by completing the « Single Site Testing » or « Gene Specific Testing » section beneath the comprehensive test on the new TRF.  Gene-specific testing may include combinations of genes ordered concurrently or as reflex tests.

How do I manage MYH-Associated Polyposis (MAP) syndrome patients?

Medical society management recommendations for MAP include colonoscopies every 1-2 years starting at age 25-30, upper endoscopies every 3-5 years starting at age 30-35, and surgical considerations. The most appropriate medical management will vary based upon your patient’s clinical presentation. For medical management references, visit References.

How do I manage patients who received a single MYH mutation result?

Medical management should be determined by clinical findings and personal and family history of colorectal polyps and/or cancer. Current data are limited but suggest that any increase in risk, if present, is likely to be small (N Engl J Med 2003;348:791-799; Lancet 2003;362:39-41; J Natl Cancer Inst 2004;96:1631-1634).